Measuring Disease Severity to Predict Patient Outcomes

Doctors need better diagnostics and biomarkers for disease severity to better treat patients and control epidemics.

We are developing a novel RNA test that quantifies immune system biomarkers to measure disease severity, predict patient outcomes early and provide potential therapeutic targets.

our method

Our Approach

Cause vs. Effect

The World Health Organization’s position is that “better diagnostics and biomarkers predicting disease severity are urgently needed.”

While current diagnostics focus on the “cause” of disease (pathogen), we target the “effect” of disease (severity). The immune system is the missing link in understanding disease severity.

Our Method

Decoding the Immune System's Signals

As the immune system is involved in virtually all diseases, decoding its signals enables revealing patient outcomes before they manifest clinically. Our proprietary immune system biomarkers allow the doctor to triage the patient and intervene medically at the earliest time point possible.

Discover how we can predict patient outcomes, regardless of disease.

Technology

In Development

Our Products

Our first product will be a qPCR Screening Test for COVID-19 severity that enables doctors to make earlier triage and intervention decisions. Our second product will be an RNA-targeted Confirmation Test that provides doctors with a detailed expression analysis revealing the clinical stage of the patient’s disease. Both products are being developed on the basis of the data generated by our clinical trial.

These products are currently being tested and are not yet available.

Applications

Early Diagnosis

How healthy or at-risk is the immune system of this patient?

Predictive Diagnosis

How should I triage this patient: hospitalize or send home?

Therapy Selection

Which therapy or vaccine should I recommend to this patient now?

Monitoring

How has severity changed since I started treating this patient?

From the Scientific Community

What Others Say About Us

“If we could look at biomarkers and understand who is going to progress to the most severe form of the disease, it also could change the therapies that we would offer to that patient. This is where we could have a tremendous impact on the whole course of a disease.”
Dr. Patricia Winokur, Executive DeanCarver College of Medicine, University of Iowa
Dr. Patricia Winokur, Executive Dean
“If we could identify biomarkers that are associated with a poor prognosis for COVID-19 or any other disease, then we would know – prior to that person having a poor outcome – that they were at risk for a poor outcome.”
Dr. Richard Smith, DirectorIowa Institute of Human Genetics, University of Iowa
Dr. Richard Smith, Director
“We take all the data and let the machine learning approach guide us through which genes or which transcripts or which patterns are actually important rather than putting our own bias into what we think is important.”
Dr. Henry Keen, Research ScientistIowa Institute of Human Genetics, University of Iowa
Dr. Henry Keen, Research Scientist
“FBB Biomed’s research does not look into single values of the immune status but looks at the history of the immune system and gives a complete picture of what has happened to that individual person.”
Dr. Heinz Hänel, Advisor to FBB BiomedHonorary Professor, Goethe University
Dr. Heinz Hänel, Advisor to FBB Biomed